ATP1A3 and alternating hemiplegia of childhood: Furthermore, our editing approaches may inform treatments for other ATP1A3-associated disorders.6 This work demonstrates that rapidly optimizing multiple correction agents in parallel may be feasible for diseases like AHC with many pathogenic variants, and developing gene editing tools capable of simultaneously modifying hundreds of bases or inserting gene-sized (>5 kb) cargos141–144 may also maximize patient eligibility for genome editing therapies.